Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 9/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | PDE5A | O76074 | 2/20 | 0.43 |
| ▸ | PDE9A | O76083 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2820871 | 1.00 | HSP90AA1 (1.00) | HSP90AA1MAPTMEN1CYP1A2CYP3A4 | |
| SCHEMBL29598579 | 1.00 | HSP90AA1 (1.00) | HSP90AA1MAPTMEN1CYP1A2CYP3A4 | |
| SCHEMBL5632986 | 0.91 | HSP90AA1 (0.83) | HSP90AA1MAPTMEN1CYP1A2CYP3A4 | |
| SCHEMBL29948904 | 0.91 | HSP90AA1 (0.83) | HSP90AA1MAPTMEN1CYP1A2CYP3A4 | |
| SCHEMBL29748943 | 0.91 | HSP90AA1 (0.83) | HSP90AA1MAPTMEN1CYP1A2CYP3A4 | |
| SCHEMBL3102522 | 0.91 | HSP90AA1 (0.83) | HSP90AA1MAPTMEN1CYP1A2CYP3A4 | |
| SCHEMBL12288836 | 0.91 | HSP90AA1 (0.83) | HSP90AA1MAPTMEN1CYP1A2CYP3A4 | |
| SCHEMBL9118693 | 0.89 | HSP90AA1 (0.81) | HSP90AA1MAPTMEN1CYP1A2CYP3A4 | |
| SCHEMBL2564507 | 0.89 | HSP90AA1 (0.81) | HSP90AA1MAPTMEN1CYP1A2CYP3A4 | |
| SCHEMBL5132212 | 0.88 | HSP90AA1 (0.78) | HSP90AA1MAPTMEN1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117045648-A | Use of BK channel openers for the treatment of osteoporosis | 复旦大学 | 2023-11-14 | — | — | CN | claimed |
| US-20260078180-A1 | ANTI-PAR2 ANTIBODIES AND USES THEREOF | MEDIMMUNE LTD (GB) | 2026-03-19 | — | — | US | disclosed |
| EP-4153170-B1 | MAXI-K POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF FRAGILE X ASSOCIATED DISORDERS | SERVIER LAB (FR) | 2026-01-21 | — | — | EP | disclosed |
| EP-4681726-A2 | ANTI-PAR2 ANTIBODIES AND USES THEREOF | MedImmune Limited (GB) | 2026-01-21 | — | — | EP | disclosed |
| EP-3596125-B1 | ANTI-PAR2 ANTIBODIES AND USES THEREOF | MEDIMMUNE LTD (GB) | 2025-11-19 | — | — | EP | disclosed |
| US-20250205306-A1 | USE OF FOLLISTATIN-LIKE 1 (FSTL1) IN CARDIOMETABOLIC HEART FAILURE | REGENCOR, INC. | 2025-06-26 | — | — | US | disclosed |
| US-20250078957-A1 | Unsupervised Machine Learning Methods | AMPEL BIOSOLUTIONS LLC (US) | 2025-03-06 | — | — | US | disclosed |
| EP-4499125-A1 | USE OF FOLLISTATIN-LIKE 1 (FSTL1) IN CARDIOMETABOLIC HEART FAILURE | Regencor, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| US-20250022541-A1 | Unsupervised Machine Learning Methods | AMPEL BIOSOLUTIONS LLC (US) | 2025-01-16 | — | — | US | disclosed |
| CN-119212718-A | Use of follistatin-like protein 1 (FSTL 1) in heart metabolic heart failure | 雷根科公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-117045648-A | Use of BK channel openers for the treatment of osteoporosis | 复旦大学 | 2023-11-14 | — | — | CN | disclosed |
| WO-2023183933-A1 | USE OF FOLLISTATIN-LIKE 1 (FSTL1) IN CARDIOMETABOLIC HEART FAILURE | REGENCOR, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| CN-110446720-B | anti-PAR 2 antibodies and uses thereof | 免疫医疗有限公司 | 2023-09-12 | — | — | CN | disclosed |
| WO-2023158713-A1 | UNSUPERVISED MACHINE LEARNING METHODS | AMPEL BIOSOLUTIONS, LLC (US) | 2023-08-24 | — | — | WO | disclosed |
| US-20230242639-A1 | ANTI-PAR2 ANTIBODIES AND USES THEREOF | MEDIMMUNE LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| US-20230218577-A1 | USE OF HEAT SHOCK PROTEIN INHIBITORS FOR THE TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-07-13 | — | — | US | disclosed |
| EP-4153170-A1 | MAXI-K POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF FRAGILE X ASSOCIATED DISORDERS | Kaerus Bioscience Limited (GB) | 2023-03-29 | — | — | EP | disclosed |
| US-11591389-B2 | Nucleic acids encoding anti-PAR2 antibodies and uses thereof | MEDIMMUNE LIMITED (GB) | 2023-02-28 | — | — | US | disclosed |
| CN-115666554-A | Novel Maxi-K potassium channel openers for the treatment of fragile X related disorders | 凯鲁斯生物科技有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20220152228-A1 | COMPOSITIONS AND METHODS FOR RADIOTHERAPY USING CHELATED RADIOTHERAPEUTIC AGENTS AND NON-TARGET TISSUE BLOCKADE | WASHINGTON UNIVERSITY (US) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078180-A1 | ANTI-PAR2 ANTIBODIES AND USES THEREOF | VSIG8, IGLV6-57, FCGR3B | HSP90AA1 3880/4885MAPT 4515/4885MEN1 2585/4885 |
| US-20230218577-A1 | USE OF HEAT SHOCK PROTEIN INHIBITORS FOR THE TREATMENT OF NEURODEVELOPMENTAL DISORDERS | HSP90AB1, HSP90AA1, HSF1 | HSP90AA1 2/4885MAPT 71/4885MEN1 3501/4885 |
| US-20220152228-A1 | COMPOSITIONS AND METHODS FOR RADIOTHERAPY USING CHELATED RADIOTHERAPEUTIC AGENTS AND NON-TARGET TISSUE BLOCKADE | VDAC1, SLC8B1, CACNA1G | HSP90AA1 1063/4885MAPT 3644/4885MEN1 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.